Menu Search
Equities

Vistin Pharma ASA

VISTN:OSL

Vistin Pharma ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)25.00
  • Today's Change0.10 / 0.40%
  • Shares traded22.18k
  • 1 Year change+12.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Vistin Pharma ASA grew revenues 51.35% from 287.68m to 435.39m while net income improved from a loss of 4.72m to a gain of 45.60m.
Gross margin64.84%
Net profit margin14.49%
Operating margin19.52%
Return on assets15.85%
Return on equity20.06%
Return on investment19.26%
More ▼

Cash flow in NOKView more

In 2023, Vistin Pharma ASA increased its cash reserves by 1,726.06%, or 24.77m. The company earned 90.59m from its operations for a Cash Flow Margin of 20.81%. In addition the company used 17.68m on investing activities and also paid 48.14m in financing cash flows.
Cash flow per share1.81
Price/Cash flow per share13.80
Book value per share7.01
Tangible book value per share7.01
More ▼

Balance sheet in NOKView more

Vistin Pharma ASA uses little debt in its capital structure as supported by a debt to capital ratio of 1.78%.
Current ratio2.13
Quick ratio1.06
Total debt/total equity0.0182
Total debt/total capital0.0178
More ▼

Growth rates in NOK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 1,066.82%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
Div yield(5 year avg)2.63%
Div growth rate (5 year)--
Payout ratio (TTM)36.13%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		37.89
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.